BRAF and melanoma: Therefore, we next determined the effect of fisetin, sorafenib and their combination on invasion of BRAF-mutated A375 and SK-MEL-28 melanoma cells by employing Boyden chambers in which cells were separated by matrigel coated membranes into two chambers containing different concentrations of growth factors.